- Home
- WNEB vs FENC Comparison
WNEB vs FENC Comparison
Compare WNEB & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | FENC |
|---|---|---|
| Founded | 1853 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.2M | 276.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | WNEB | FENC |
|---|---|---|
| Price | $13.13 | $7.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $15.00 |
| AVG Volume (30 Days) | 45.2K | ★ 179.1K |
| Earning Date | 01-28-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 27.15 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $79,080,000.00 | $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | $70.97 |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $7.63 | $4.68 |
| 52 Week High | $13.95 | $9.92 |
Technical Indicators
Market Signals| Indicator | WNEB | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 48.02 |
| Support Level | $12.47 | $7.35 |
| Resistance Level | $13.25 | $7.82 |
| Average True Range (ATR) | 0.31 | 0.39 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 77.57 | 31.06 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.